Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zoetis (NY:ZTS)

146.85 -1.32 (-0.89%)
Official Closing Price Updated: 7:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zoetis

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. 
Via Benzinga
Animal Health Giant Zoetis Stock Crumbles: Possible Side Effect Of Its Pet Arthritis Pain Drugs Sickened Dogs, Cats
Zoetis' Solensia and Librela, pioneering arthritis treatments for pets. Despite recent concerns, Zoetis defends their safety record, emphasizing positive outcomes for millions of treated animals. 
Via Benzinga
A Closer Look at Zoetis's Options Market Dynamics
Via Benzinga
Zoetis Stock Crumbles After Report Suggests Arthritis Shots Sickened Dogs, Cats
The company says the side effects represent a fraction of the 18 million injections given in the U.S. and abroad. 
Via Investor's Business Daily
(ZTS) - Analyzing Zoetis's Short Interest
Via Benzinga
Expert Outlook: Zoetis Through The Eyes Of 4 Analysts
Via Benzinga
Here's How Much You Would Have Made Owning Zoetis Stock In The Last 10 Years
Via Benzinga
How's AT&T Handling Things?
We've also got a look at 3M's spinoff, gold prices, and the beef industry. 
Via The Motley Fool
Is It Time to Buy the S&P 500's 3 Worst-Performing Stocks of March?
The S&P 500 rose last month, but these stocks didn't. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine
The European Commission launches probe into Zoetis over alleged market interference in dog pain medication launch. Focus on Zoetis' Librela monoclonal antibody for osteoarthritis pain relief in dogs... 
Via Benzinga
Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Looking Into Zoetis's Recent Short Interest
Via Benzinga
4 Analysts Have This To Say About Zoetis
Via Benzinga
(ZTS) - Analyzing Zoetis's Short Interest
Via Benzinga
1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now
Buoyed by megatrends in animal healthcare, this stock makes for an excellent holding in almost any portfolio. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Zoetis (ZTS) Q4 2023 Earnings Call Transcript
ZTS earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Animal Health-Focused Zoetis Stock Faces Near-Term Pressure, Analyst Cites Uncertainty In Q4 Results, Weak Margins
Zoetis' Q4 2023 performance with $2.21 billion revenue, 8% YoY growth, and strong sales in companion animal products. 
Via Benzinga
Is ZOETIS INC (NYSE:ZTS) a Strong Candidate for Quality Investing?
Why Quality Investors Should Delve into ZOETIS INC (NYSE:ZTS) for Investment Opportunities. 
Via Chartmill
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
Via Benzinga
What 4 Analyst Ratings Have To Say About Zoetis
Via Benzinga
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
Will ZOETIS INC Break Out? A Technical Analysis Perspective.
ZOETIS INC (NYSE:ZTS) has a strong technical rating of 10 out of 10, indicating a potential breakout. 
Via Chartmill
Drug Maker AbbVie Stock Sees RS Rating Jump To 81
AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81. 
Via Investor's Business Daily
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
Paws And Prosperity: Exploring U.S. Pet Services Growth And The Anticipated Surge In Annual Pet Spending From $980 To $1,292 By 2025
The number of U.S. homes with pets has been trending upward for decades, with more than 5 million more pets in the U.S. than before the pandemic. Beyond the pandemic-driven boom, the trends continue,... 
Via Benzinga
AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow
AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
4 Magnificent Stocks I'm Done Waiting on a Dip for in 2024 -- but I'm Not Buying Them Hand Over Fist, Either
These stocks never seem to go on sale. Here's why I'm buying them anyway. 
Via The Motley Fool
Stifel: ‘Party Is Just Getting Started’ In This Stock That's Up 80%
Animal-pharma company Elanco Animal Health, once a subsidiary of Lilly, looks especially good with its new treatment for parvovirus in dogs. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.